Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine-Reference-Cited by-同舟云学术

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine

Published:2022-01-13 Issue:2 Volume:6 Page:368-372
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Zátopková Martina¹²³^ORCID,Ševčíková Tereza¹²³^ORCID,Fanfani Viola⁴^ORCID,Chyra Zuzana¹²⁵^ORCID,Říhová Lucie⁶^ORCID,Bezděková Renata⁶,Žihala David¹²³^ORCID,Growková Kateřina¹²³,Filipová Jana¹,Černá Lucie¹,Broskevičova Lucie²,Kryukov Fedor⁷,Minařík Jiří⁸^ORCID,Smejkalová Jana²,Maisnar Vladimír⁹,Harvanová Ĺubica¹⁰,Pour Luděk¹¹,Jungova Alexandra¹²,Popková Tereza²^ORCID,Bago Juli Rodriguez¹²^ORCID,Anilkumar Sithara Anjana¹²,Hrdinka Matouš¹²^ORCID,Jelínek Tomáš¹²³^ORCID,Šimíček Michal¹²³^ORCID,Stracquadanio Giovanni⁴^ORCID,Hájek Roman¹²

Affiliation:

1. Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;

2. Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic;

3. Department of Biology and Ecology, University of Ostrava, Ostrava, Czech Republic;

4. Institute of Quantitative Biology, Biochemistry and Biotechnology, University of Edinburgh, Edinburgh, United Kingdom;

5. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

6. Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic;

7. Clinical Development Department, Joint-stock Company BIOCAD, Saint Petersburg, Russia;

8. Department of Hematooncology, University Hospital and Palacky University Olomouc, Olomouc, Czech Republic;

9. 4th Department of Medicine–Haematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic;

10. Department of Hematology and Transfusiology, University Hospital Bratislava, Bratislava, Slovakia;

11. Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic; and

12. Department of Hemato-Oncology, Charles University Hospital Pilsen, Pilsen, Czech Republic

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/6/2/368/1859261/advancesadv2020003876.pdf

Reference24 articles.

1. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis;Munshi;JAMA Oncol.,2017

2. Clonal evolution in myeloma: a narrow road to remission;Miething;Haematologica.,2019

3. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma;Walker;J Clin Oncol.,2015

4. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy;Lohr;Cancer Cell.,2014

5. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma;Bolli;Nat Commun,2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma;Clinical Cancer Research;2022-10-25

2. Application of precision medicine in clinical routine in haematology—Challenges and opportunities;Journal of Internal Medicine;2022-06-04

3. The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: Where are we now and which questions remain unanswered?;British Journal of Haematology;2022-05-05